Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study
- PMID: 8936350
- DOI: 10.1007/BF00868517
Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study
Abstract
Acyclovir treatment was used in a randomized, double-blind, placebo-controlled clinical trial with parallel groups to test the hypothesis that herpes virus infections are involved in the pathogenesis of multiple sclerosis (MS). Sixty patients with the relapsing-remitting form of MS were randomized to either oral treatment with 800 mg acyclovir or placebo tablets three times daily for 2 years. The clinical effect was investigated by an extensive test battery consisting of neurological examinations, neuro-ophthalmological and neuropsychological tests, and evoked potentials. Results were based on "intent-to-treat" data and the primary outcome measure was the exacerbation rate. In the acyclovir group (n = 30), 62 exacerbations were recorded during the treatment period, yielding an annual exacerbation rate of 1.03. The placebo group (n = 30) had 94 exacerbations and an annual exacerbation rate of 1.57. Thus, 34% fewer exacerbations were encountered during acyclovir treatment. This difference in exacerbation rate between the treatment groups was not significant (P = 0.083). However, this trend to a lower disease activity in acyclovir-treated patients was supported in subsequent data analysis. If the patients were grouped according to exacerbation frequencies, i.e. into low (0-2), medium (3-5) and high (6-8) rate groups, the difference between acyclovir and placebo treatment was significant (P = 0.017). Moreover, in a subgroup of the population with a duration of the disease of at least 2 years providing an exacerbation rate base-line before entry, individual differences in exacerbation rates were compared between the 2-year pre-study period and the study period in acyclovir-treated (n = 19) and placebo (n = 20) patients and acyclovir-treated patients showed a significant reduction of exacerbations (P = 0.024). Otherwise, neurological parameters were essentially unaffected by acyclovir treatment and there were no convincing signs of reduced neurological deterioration in the acyclovir group. This study indicates that acyclovir treatment might inhibit the triggering of MS exacerbations and thus suggests that acyclovir-susceptible viruses might be involved in the pathogenesis of MS. This possibility warrants further investigation.
Similar articles
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.Neurology. 2002 Jan 8;58(1):31-6. doi: 10.1212/wnl.58.1.31. Neurology. 2002. PMID: 11781402 Clinical Trial.
-
Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.Antiviral Res. 1999 Feb;41(1):1-19. doi: 10.1016/s0166-3542(98)00067-9. Antiviral Res. 1999. PMID: 10321575 Free PMC article. Review.
-
A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.Arch Dermatol. 1998 Feb;134(2):185-91. doi: 10.1001/archderm.134.2.185. Arch Dermatol. 1998. PMID: 9487210 Clinical Trial.
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304. Ann Neurol. 1996. PMID: 8602746 Clinical Trial.
Cited by
-
From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment.Biomedicines. 2023 Nov 16;11(11):3069. doi: 10.3390/biomedicines11113069. Biomedicines. 2023. PMID: 38002068 Free PMC article. Review.
-
Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.Infect Drug Resist. 2023 Jul 13;16:4599-4620. doi: 10.2147/IDR.S375624. eCollection 2023. Infect Drug Resist. 2023. PMID: 37465179 Free PMC article. Review.
-
Alzheimer's disease and multiple sclerosis: a possible connection through the viral demyelinating neurodegenerative trigger (vDENT).Front Aging Neurosci. 2023 Jun 15;15:1204852. doi: 10.3389/fnagi.2023.1204852. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37396655 Free PMC article.
-
Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.Front Neurosci. 2022 Mar 1;16:817067. doi: 10.3389/fnins.2022.817067. eCollection 2022. Front Neurosci. 2022. PMID: 35299622 Free PMC article.
-
Semi-parametric analysis of overdispersed count and metric data with varying follow-up times: Asymptotic theory and small sample approximations.Biom J. 2019 May;61(3):616-629. doi: 10.1002/bimj.201800027. Epub 2018 Dec 5. Biom J. 2019. PMID: 30515878 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical